之江生物(688317)
 
 
  日线
顶尖财经网欢迎您!
  K线
 
 最新动态
  投资评级

研究机构 评级日期 最新评级 上次评级
暂无数据
  盈利预测
据之江生物三季报分析:

  盈利能力明显恶化,总资产收益能力急剧下降

  成长能力明显恶化,营业收入由增长转为下降

  偿债能力有所加强,偿还流动负债能力很强

  运营能力明显恶化,产品市场竞争力明显减弱

  现金流能力明显恶化,现金满足投资能力被严重削弱

  财务数据
    截至第三季度实现净利润0.35亿元,每股收益0.18元。

    截至第三季度最新股东权益399617.32万元,未分配利润166073.20万元。

    截至第三季度最新总资产422376.63万元,负债22759.30万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入205,201,872.85146,918,051.3384,348,212.482,326,255,117.23
营业总成本166,756,990.8110,791,802.0675,183,122.671,472,611,375.92
营业利润52,638,760.147,094,497.3710,063,921.65907,364,782.14
利润总额46,416,843.0340,851,881.436,896,289.86901,483,626.27
净利润34,641,306.8131,619,600.256,026,571.66760,273,479.93
其他综合收益-9,505,020.43727,403.45-2,368,529.86-19,618,382.73
综合收益总额25,136,286.3832,347,003.713,658,041.8740,655,097.2
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计3,401,779,972.873,447,390,099.873,697,046,928.723,909,848,957.27
非流动资产合计821,986,293.88830,775,723.83827,593,365.35834,002,348.07
资产总计4,223,766,266.754,278,165,823.74,524,640,294.074,743,851,305.34
流动负债合计213,179,069.1263,438,628.51302,602,162.64523,862,914.18
非流动负债合计14,413,980.2516,077,352.4417,968,432.2319,576,733.76
负债合计227,593,049.35279,515,980.95320,570,594.87543,439,647.94
归属于母公司股东权益合计3,996,173,217.43,998,649,842.754,204,069,699.24,200,411,657.4
股东权益合计3,996,173,217.43,998,649,842.754,204,069,699.24,200,411,657.4
负债和股东权益合计4,223,766,266.754,278,165,823.74,524,640,294.074,743,851,305.34
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计356,878,605.48245,621,184.28121,883,701.382,540,566,000.42
经营活动现金流出小计502,131,973.57423,213,369.24293,765,724.111,955,594,864.96
经营活动产生的现金流量净额-145,253,368.09-177,592,184.96-171,882,022.73584,971,135.46
投资活动现金流入小计7,215,805.63570,796.47160,00049,737,076.04
投资活动现金流出小计49,523,158.4233,919,996.442,194,813.73125,757,603.2
投资活动产生的现金流量净额-42,307,352.79-33,349,199.93-42,034,813.73-76,020,527.16
筹资活动现金流入小计----
筹资活动现金流出小计233,158,750.37230,742,546.11-371,404,022.3
筹资活动产生的现金流量净额-233,158,750.37-230,742,546.11--371,404,022.3
汇率变动对现金及现金等价物的影响31,028,033.2237,866,173.97-10,541,921.4374,353,777.98
现金及现金等价物净增加额-389,691,438.03-403,817,757.03-224,458,757.88211,900,363.98
期末现金及现金等价物余额2,758,032,313.852,743,657,793.192,923,264,9943,147,475,550.22
  主营收入+营业利润
 
  净利润+每股收益
  股东权益+未分配利润
 
  总资产+负债
  投资要点

    截至第三季度实现净利润0.35亿元,每股收益0.18元。

    截至第三季度最新股东权益399617.32万元,未分配利润166073.20万元。

    截至第三季度最新总资产422376.63万元,负债22759.30万元。

利润表
报告期2023-09-302023-06-302023-03-312022-12-31
营业总收入205,201,872.85146,918,051.3384,348,212.482,326,255,117.23
营业总成本166,756,990.8110,791,802.0675,183,122.671,472,611,375.92
营业利润52,638,760.147,094,497.3710,063,921.65907,364,782.14
利润总额46,416,843.0340,851,881.436,896,289.86901,483,626.27
净利润34,641,306.8131,619,600.256,026,571.66760,273,479.93
其他综合收益-9,505,020.43727,403.45-2,368,529.86-19,618,382.73
综合收益总额25,136,286.3832,347,003.713,658,041.8740,655,097.2
资产负债表
报告期2023-09-302023-06-302023-03-312022-12-31
流动资产合计3,401,779,972.873,447,390,099.873,697,046,928.723,909,848,957.27
非流动资产合计821,986,293.88830,775,723.83827,593,365.35834,002,348.07
资产总计4,223,766,266.754,278,165,823.74,524,640,294.074,743,851,305.34
流动负债合计213,179,069.1263,438,628.51302,602,162.64523,862,914.18
非流动负债合计14,413,980.2516,077,352.4417,968,432.2319,576,733.76
负债合计227,593,049.35279,515,980.95320,570,594.87543,439,647.94
归属于母公司股东权益合计3,996,173,217.43,998,649,842.754,204,069,699.24,200,411,657.4
股东权益合计3,996,173,217.43,998,649,842.754,204,069,699.24,200,411,657.4
负债和股东权益合计4,223,766,266.754,278,165,823.74,524,640,294.074,743,851,305.34
现金流量表
报告期2023-09-302023-06-302023-03-312022-12-31
经营活动现金流入小计356,878,605.48245,621,184.28121,883,701.382,540,566,000.42
经营活动现金流出小计502,131,973.57423,213,369.24293,765,724.111,955,594,864.96
经营活动产生的现金流量净额-145,253,368.09-177,592,184.96-171,882,022.73584,971,135.46
投资活动现金流入小计7,215,805.63570,796.47160,00049,737,076.04
投资活动现金流出小计49,523,158.4233,919,996.442,194,813.73125,757,603.2
投资活动产生的现金流量净额-42,307,352.79-33,349,199.93-42,034,813.73-76,020,527.16
筹资活动现金流入小计----
筹资活动现金流出小计233,158,750.37230,742,546.11-371,404,022.3
筹资活动产生的现金流量净额-233,158,750.37-230,742,546.11--371,404,022.3
汇率变动对现金及现金等价物的影响31,028,033.2237,866,173.97-10,541,921.4374,353,777.98
现金及现金等价物净增加额-389,691,438.03-403,817,757.03-224,458,757.88211,900,363.98
期末现金及现金等价物余额2,758,032,313.852,743,657,793.192,923,264,9943,147,475,550.22
  十大流通股东
十大流通股东 报告期:2023-09-30
股东名称 持股数量(万股) 占总股本比例(%) 上期持股变化(万股)
宁波睿道创业投资合伙企业(有限合伙)362.842.93-1.30
上海能发投资咨询有限公司350.002.830.00
富诚海富资管-杭州银行-富诚海富通之江1号员工参与科创板战略配售集合资产管理计划234.291.89-4.79
中国银行股份有限公司-大成景恒混合型证券投资基金161.391.3068.52
上海迈景纳米科技有限公司160.001.290.00
徐春辉159.621.29-25.70
海通创新证券投资有限公司121.030.980.00
香港中央结算有限公司105.320.85105.32
叶国林99.970.814.47
张惠燕66.100.53-2.47
  主力控盘
  公司简介
之江生物 所属地域: -- 涉及概念: 流感,创新药,食品安全,抗原检测,沪股通,猴痘概念,猴痘概念,肝炎概念,新冠治疗,幽门螺杆菌概念,专精特新,融资融券
主营业务: 生物技术的研究开发,生物技术咨询,化学试剂(除危险化学品、监控化学品、烟花爆竹、民用爆炸物品、易制毒化学品)的零售;货物的进出口;医疗器械的销售(具体经营范围见许可证);III类6840医用体外诊断试剂的生产。【依法须经批准的项目,经相关部门批准后方可开展经营活动】
上市日期: 2021-01-18 每股净资产: 20.52元 每股收益: 0.18元 净利润: 0.35亿元 净利润增长率: -94.49%
营业收入: 2.05亿元 每股现金流: -0.75元 每股公积金: 11.04元 每股未分配利润: 8.53元 总股本: 1.95亿 流通股: 1.24亿
以上信息为合作方、加盟公司及会员收集,本站不拥有版权,版权归原作者所有,所载文章、数据仅供参考,据此操作,风险自负。

中 华 顶 尖 财 经 -- 中 华 顶 尖 网 络 信 息 服 务 中 心